EP0404812A1 - Proteine recombinante de liaison d'igf (facteur de croissance analogue a l'insuline) (ibp-1) - Google Patents

Proteine recombinante de liaison d'igf (facteur de croissance analogue a l'insuline) (ibp-1)

Info

Publication number
EP0404812A1
EP0404812A1 EP89903815A EP89903815A EP0404812A1 EP 0404812 A1 EP0404812 A1 EP 0404812A1 EP 89903815 A EP89903815 A EP 89903815A EP 89903815 A EP89903815 A EP 89903815A EP 0404812 A1 EP0404812 A1 EP 0404812A1
Authority
EP
European Patent Office
Prior art keywords
igf
binding protein
insulin
protein
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP89903815A
Other languages
German (de)
English (en)
Inventor
Stenwert Leonard Sebastian Drop
Arend Brinkman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasmus Universiteit Rotterdam
Original Assignee
Erasmus Universiteit Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus Universiteit Rotterdam filed Critical Erasmus Universiteit Rotterdam
Publication of EP0404812A1 publication Critical patent/EP0404812A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • IBP-1 Recombinant IGF binding protein
  • the present invention relates to an Insulin-like Growth Factor Binding Protein, IBP-1, having a molecular weight of about 28 kD, derived from human placenta/endometrium, and equivalent modifications thereof.
  • IBP-1 Insulin-like Growth Factor Binding Protein
  • the invention further relates to a DNA-structure, coding for the IBP-1, expression vectors containing this DNA-structure and procaryotic or eucaryotic cells comprising such a vector.
  • the invention still further relates to pharmaceutical preparations comprising IBP-1.
  • IGF insuline-like growth factor
  • NGF nerve growth factor
  • IGF-I and IGF-II are unique in that they are complexed to specific binding proteins in plasma (Smith, 1984).
  • binding protein 53 BP-53
  • IBP-1 a GH dependent binding protein, believed to be derived from the 150 kD complex which carries most of the endogenous IGF peptides
  • IBP-1 an IGF binding protein of about 30-40 kD which is tissue specifically expressed in endometrium and liver and accounts for most of the unsaturable binding sites in plasma. While the 53 kD-binding protein is under GH control the 30-40 kD species appears to be expressed in a GH independent way.
  • the lower molecular weight binding protein was initially identified in human amniotic fluid and has been purified and characterized (Chochinov et al., 1977; Drop et al., 1979; Drop et al., 1982).
  • This 30-40 kD IGF binding protein appears to be identical to binding proteins that have been purified from human serum and the human hepatoma cell line, HEPG2 (Drop et al., 1984a; Povoa et al., 1984; Povoa et al., 1985).
  • Povoa et al showed that the NH 2 -terminal amino acid sequence of the binding protein found in amniotic fluid and from the HEPG2 cell line are similar (Povoa et al., 1985).
  • Placental protein PP12 a protein originally isolated from human placenta, was found to bind IGF as well as to have an identical NH 2 -terminal amino acid sequence (Koistinen et al., 1986).
  • IGF-binding protein Stimulatory effects of IGF-binding protein has been shown in at least two cases. Clemmons et al (1986) showed increased binding to fibroblast and smooth muscle cell surface receptors of IGF in complex with its binding protein. Inhibitory effects of IGF-binding protein on various IGF actions in vitro, including stimulation of glucose transport by adipocytes, sulphate incorporation by chondrocytes and thymidine incorporation in fibroblasts have been described ( Zapf et al., 1979; Drop et al.,
  • the IGF-binding protein has the following amino acid sequence:
  • the protein according to the invention may be used as an effective potentiator for the functioning of somatomedins.
  • the effect can be mediated through the firm binding between the somatomedins and their binding proteins under physiological conditions.
  • Such complexed somatomedins together with their binding proteins are protected against undue proteolysis, causing a significant increase of the biological half life of somatomedins.
  • this IGF-binding protein or modifications hereof might function as a potent carrier of IGF to its local sites of action.
  • IBP-1 As IGF-binding protein, or modifications thereof, such as alpha 1 PEG, are the major secretory soluble protein of decidual cells of the endometirum, IBP-1 may have an important function in restricting trophoblast invasion into the endometrium during placental development. Furthermore, the inhibitory function of IBP-1 in cellular proliferation assays and the unexpected direct inhibitoryeffect of IBP-1 on the oestrogen response on certain cancer cells make IBP-1 or modifications hereof a potential anticancer reagent with local growth inhibitoryeffect.
  • fig. 1 illustrates a restriction map and sequence strategy for human 28 kD IGF binding protein cDNA clones
  • fig. 2 shows the nucleotide and deducted amino acid sequence of human IGF binding protein where differences between the placental cDNA sequence and the liver cDNA sequence are shown in parenthesis
  • fig. 3 represents an SDS/PAGE analysis of culture media of COS-1 cells transfected with pSV19, pSV4, pSV4Inv and untransfected COS-1 cells.
  • the cDNA encoding IGF-BP was obtained by screening a human placental and a human hepatoma (HEPG-2) cDNA- expression library with a polyclonal antibody to human amniotic fluid binding protein (Drop et al., 1984a).
  • the complete nucleotide sequence of the cDNA insert of one of the clones isolated (p19) was determined.
  • the 1421 nucleotide sequence shown in fig. 2 contains a 5' untranslated region of 52 nucleotides followed by an ATG codon and an open reading frame of 776 nucleotides.
  • the potential initiation codon is flanked by 5 sequences matching Kozak's criteria for an initiation codon (Kozak, 1986).
  • the open reading frame is flanked by a translation termination codon (TGA) and a 569 nucleotides long 3' untranslated sequence.
  • the open reading frame in cDNA clone p19 has a coding capacity for a protein of 259 residues also shown in figure 2 (by the one-letter code), with a calculated Mw of 28,172 daltons.
  • the initiation methione is the first amino acid of a 24-residue highly hydrophobic peptide sequence (underlined), representing the sequence of a putative signal sequence necessary for transfer of .the nascent polypeptide sequence into the membranes of the endoplasmatic reticulim.
  • a favourable signal peptidase cleavage site (ala-gly) occurs immediately N-terminally of the alanine residue at pos +1 (von Heijne, 1987).
  • the NH 2 -terminus of the predicted mature protein is identical to the chemically determined NH 2 -terminus described for the IGF-binding protein isolated both from amniotic fluid (Povoa et al., 1984), and from the HEPG2 cell line (Povoa et al., 1985) and from serum (Baxter et al., 1987).
  • the M r of this gene product is predicted to be 2,350 daltons.
  • the M r of serum IGF binding protein is about 28,000 daltons (Baxter et al., 1987). The difference is believed to be accounted for by glycosylation of the IGF binding protein (Bohn et al., 1980; Koistinen et al., 1986).
  • the amino acid sequence did not disclose N-linked glycosylation sites (N-T, N-S). However, at least five potential O-linked glycosylation sites were found in the NH 2 -terminal of the molecule.
  • a RGD sequence in the COOH terminal part of the IBP-1 protein has been found. Such a short sequence is considered to be important for cellular attachment of matrix proteins, such as fibronectin, vitronectin and von Willebrand factor, to receptors of the integrin family.
  • IBP-1 in mammalian cells.
  • Expression vectors, pSV19, pSV4 and pSV4Inv were constructed by inserting the full length clones p4 and p19 in the expression vector pSV328.
  • the vectors pSV4, pSVl9 and pSV4Inv, in which the cDNA insert is in 3' - 5' orientation, were transfected to COS-1 cells.
  • COS-1 cells transfected with pSV19 (lane A), pSV4 (lane B), and amniotic fluid (lane C) were analysed.
  • the IGF binding proteins were made visible by immuno staining as described for the screening of the cDNA libraries.
  • culture media of pSV4 and pSV19 transfected COS-1 cells in which the gene is in the correct orientation a protein of 32 kD being immunologically indistinguishable from the IGF binding protein from amniotic fluid (fig. 3) was detected.
  • a band was visible which reacted with the 35 kD SMBP antibody but which was absent in the culture medium from untransfected COS-1 cells.
  • IBP-1 successfully has been expressed in COS-1 cells the lack of N-linked glycosylation sites in the putative protein also favour expression in yeast and bacteria to increase the IBP-1 production to be used in a variety of therapeutic compositions.
  • compositions comprising IBP-1 or derivatives thereof and pharmacologically acceptable excipients.
  • Such compositions including the IGF-binding protein or derivatives hereof according to this invention have many therapeutic uses involving the physiological functions of somatomedins.
  • the IGF-binding protein of the invention may be formulated as pharmaceutical preparations comprising the IGF-binding protein of the invention together with the usual excipients.
  • Pharmaceutical preparations according to the invention may be in the form of suspension or solutions for parentheral administration, e.g. i.v., s.c, i.m., implants, subcutaneous or interveneous administration or administration through the mucosa, e.g. oral, nasal, buccal, sublingual or rectal administration or transdermal administration.
  • IBP-1 describes in this invention hereby abolishes the potent mitogenic effect of the somatomedins that administrated in high dosis, i.e. intra venously, would cause unwanted local cellular proliferations in a variety of cells like fibroblasts, muscle cells and endothelial cells.
  • IBP-1 described by this invention administred together with IGF-1, IGF-2 and other growth factors or formulated as common preparations for topical use (such as PDGF, EGF, FGF, TGFalpha or TGFbetha) employed in therapeutical devices to be used in healing of wounds or in treatment of oeteoporosis and in healing of bones might be valuable for a steady and controlled release of the somatomedins in such therapeutical devices.
  • topical use such as PDGF, EGF, FGF, TGFalpha or TGFbetha
  • Such preparations may optionally be administred in the form of combination preparations e.g. comprising IBP-1 and IGF-1, IBP-1 and IGF-2 or IBP-1, IGF-1 and IGF-2.
  • IBP-1 in general, might turn out to exhibit a potent regulatory function in the release of IGF-1 and/or IGF-2 in future treatment of injuries or other malfunctions that requires increased IGF-1 and/or IGF-1 levels.
  • IBP-1 or derivatives thereof according to this invention might be useful in therapy of the proliferation of certain cancers characterized by producing somatomedins in high amounts thus inhibiting the autocrine/paracrine physiological stimulation of unwanted cellular proliferation in cancers like chondrosarcomas, fibrosarcomas, and mammacarcinomas.
  • IBP-1 or derivatives hereof described in this invention is useful for the production of antibodies.
  • Such mono- or polyclonal antibodies are suitable for developing immunological methods like immunohistochemical analysis of IBP-1 in tissues and for developing ELISA for IBP-1 quantitation.
  • ELISA will prove valuable for early screening the levels of IBP-1 in patients with altered IGF-1 and 2 levels.
  • preservatives phenol and m-cresol.
  • examples of an isotonic agent sodium chloride and glycerol.
  • Example of buffer is sodium phosphate.
  • compositions of this invention for transmucosal administration can be prepared by mixing the following constituents: IBP-1 and derivatives thereof, together with IGF-1, IGF-2 and other growth factors, a buffer, an isotonic agent, a preservative, an absorption promotor and a vehicle e.g. water, cellulose, water-soluble cellulose alkylethers, crystalline cellulose, water-soluble polyacrylates or mixtures thereof.
  • a vehicle e.g. water, cellulose, water-soluble cellulose alkylethers, crystalline cellulose, water-soluble polyacrylates or mixtures thereof.
  • compositions of this invention for transdermal administration can be prepared by mixing the following constituents: IBP-1 and derivatives thereof together with IGF-1, IGF-2 and other growth factors, an isotonic agent, a preservative and a vehicle e.g. a hydrophilic gel of water-soluble cellulose alkylethers.
  • a human placenta cDNA library in lambda gtll and a cDNA library of the human hepatoma cell line HEPG2 were screened with a polyclonal antibody to human amniotic fluid binding protein according to the procedure described by Young and Davis (Young and Davis, 1982). Rabbit antibody to 35 kD somatomedin binding protein SMBP isolated from human amniotic fluid was produced and purified as described by Drop et al., 1984a.
  • the antibody was absorbed against E.coli Y1090 and lambda gtll proteins by incubating with nitrocellulose filters that had been lifted from confluent lysis plates of E.coli Y1090/lambda gtll induced with 10 mM isopropyl beta-d-thiogalacopyranoside (IPTG).
  • IPTG isopropyl beta-d-thiogalacopyranoside
  • the antibody was further absorbed against human serum albumin immobilized on nitrocellulose filters.
  • Approximately 4 x 10 5 clones of the placental library were screened and about 0.5 x 10 5 of the HPEG2 library.
  • 3-5 x 10 4 plaque forming units per 150 mm Petri dish were plated on a lawn of
  • the filters were washed and incubated for 60 min. at room temperature with horse-radish peroxydase conjugated goat anti-rabbit IgG (Tago) diluted 1:200 in 3% BSA in TBS.
  • the filters were washed and stained with amidophenyl and napthol AS-MX phosphate in 0.2 M Tris/HCl, pH 9.2, 10 mM MgCl 2 at room temperature.
  • Positive phages were isolated and DNA was isolated by standard methods (Maniatis et al., 1982). About 33 plaques strongly cross-reacting with the polyclonal antibody were identified in the placenta and HEPG2 cDNA library. Following re-screening inserts varying in size between 0.9-1.5 Kb were isolated and subcloned in the vector PTZ19 from Pharmacia. All isolated clones showed cross-hybridization in a Southern blot except one clone from the placenta library and the 5 weakly hybridizing clones from the HEPG2 library.
  • DNA was digested with various restriction endonucleases (BRL, NEN, Boehringer) according to the suppliers directions, electrophoresed in 0.8% agarose, and transferred to nitrocellulose filters according to the method of southern (Southern, 1975).
  • mRNA was denaturated with dimethylsulfozide (DMSO) and glyoxal, subjected to electrophoresis in 1% agarose and transferred to nitrocellulose filters (Millipore HFTF).
  • DMSO dimethylsulfozide
  • Millipore HFTF nitrocellulose filters
  • cDNA clones p4 and pl9 were subcloned in the EcoRl site of pSV328, which expressed cloned inserts using the simian virus 40 (SV40) early promotor (Van Heuvel et al., 1986).
  • SV40 simian virus 40
  • a DEAE-dextran procedure (McCuthchan & Pagano, 1986) followed by treatment with 100 ⁇ M chloroquine in Dulbecco's MEM (DMEM) for 4 hrs was used to transfect COS-1 cells (Gluzman, 1981). After this treatment the cells were grown 24 hrs with DMEM plus 5% foetal calf serum.
  • Proteins from amniotic fluid or from conditioned media were precipitated with ammonium sulphate at a final concentration of 35%. Following centrifugation the supernatant was brought to 50% ammonium sulphate. The pellet was dissolved in 45% ammonium sulphate and the final pellet was dissolved in 50 mM Tris HCl, pH 7.5 for further purification and characterization. The dissolved ammonium sulphate precipitate was further purified by reverse phase chromatography on C 18 . Following washings with 50 mM Tris-HCl, pH 7.5 and Tris HCl, pH 7.5 in 50% methanol the pure IBP-1 was eluted from the column with Tris-HCl, pH 7.5 in 65% methanol. The IBP-1 was precipitated overnight in a 7% Trichloroacetic-acid solution. The precipitate was dissolved in 20 mM Tris-HCl, pH 7.5, lyophilized and storred at ⁇ 20°C.
  • IBP-1 binds both IGF-1 and IGF-2 with approximately the same specificity when measured in binding assays with
  • the specificity of IBP-1 reaction was tested in similar assays employing such competition assays and in assays in which IBP-1 - IGF binding was visualized through the specific reaction of antibody against IBP-1. In such assays IBP-1 did only react with IGF-1 and IGF-2 but not with closely related compounds like insulin, proinsulin or truncated forms thereof.
  • IBP-1 and IGF-1 were dissolved and diluted in phosphate buffer containing NaCl. The pH was adjusted to 7.3-7.4.
  • IBP-1 and IGF-2 were dissolved and diluted in phosphate buffer containing glycerin, benzalconiumchlorid and sodiumedetat. The pH was adjusted to 7.4
  • the gel is prepared by mixing hydroxyethylcellulose with the waterphase containing IBP-1, IGF-1 and IGF-2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

On a mis au point une protéine de liaison d'IGF ayant la séquence d'amino acides (I) ou une modification équivalente de celle-ci, telle qu'une modification glycosylée. On a également mis au point une séquence d'ADN codant pour la protéine, un vecteur d'expression, ainsi qu'une préparation pharmaceutique contenant ladite protéine. La protéine est efficace comme élément de potentialisation pour la fonction de composés d'IGF.
EP89903815A 1988-03-11 1989-03-10 Proteine recombinante de liaison d'igf (facteur de croissance analogue a l'insuline) (ibp-1) Withdrawn EP0404812A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK131988A DK131988A (da) 1988-03-11 1988-03-11 Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
DK1319/88 1988-03-11

Publications (1)

Publication Number Publication Date
EP0404812A1 true EP0404812A1 (fr) 1991-01-02

Family

ID=8103523

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89903815A Withdrawn EP0404812A1 (fr) 1988-03-11 1989-03-10 Proteine recombinante de liaison d'igf (facteur de croissance analogue a l'insuline) (ibp-1)

Country Status (5)

Country Link
EP (1) EP0404812A1 (fr)
JP (1) JPH03504494A (fr)
AU (1) AU3296589A (fr)
DK (1) DK131988A (fr)
WO (1) WO1989008667A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5973115A (en) * 1987-05-15 1999-10-26 Amgen Inc. Method for potentiating and inhibiting insulin-like growth factor activity
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
WO1989009792A1 (fr) * 1988-04-12 1989-10-19 Synergen, Inc. Procede de potentialisation et d'inhibition de l'activite de facteurs de croissance du type insuline
US6465423B1 (en) 1988-07-15 2002-10-15 Central Sydney Area Health Service Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
US5324820A (en) * 1988-07-15 1994-06-28 Central Sydney Area Health Service Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
JP3178714B2 (ja) * 1988-07-15 2001-06-25 セントラル・シドニー・エリア・ヘルス・サービス インスリン様成長因子（ｉｇｆ）結合蛋白複合体の酸不安定サブユニット（ａｌｓ）
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
US5212074A (en) * 1990-08-28 1993-05-18 Chiron Corporation Genetic material encoding new insulin-like growth factor binding protein igfbp-6
IE913032A1 (en) * 1990-08-28 1992-03-11 Chiron Corp New insulin-like growth factor binding protein (igfbp-4)
CA2090702A1 (fr) * 1990-08-28 1992-03-01 Michael C. Kiefer Proteine igfbp-5 possedant une forte affinite pour un facteur de croissance de substances apparentees a l'insuline
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US6326154B1 (en) 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
WO1992012243A1 (fr) 1991-01-08 1992-07-23 Chiron Corporation Nouvelle proteine de fixation du facteur de croissance proche de l'insuline (igfbp-6)
US5198340A (en) * 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US6420172B1 (en) 1992-04-20 2002-07-16 Tib Company, Llc Method for inducing tumor immunity
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
AU686585B2 (en) 1992-11-04 1998-02-12 Dennis L Andress Truncated insulin-like growth factor binding proteins having mitogenic activity
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
CA2160154A1 (fr) * 1993-04-07 1994-10-13 George N. Cox Methodes d'utilisation de proteines de fixation de facteur de croissance de type insuline
JPH09503753A (ja) * 1993-08-03 1997-04-15 セルトリックス ファーマシューティカルズ，インコーポレイテッド 生殖障害の治療方法
US7026299B2 (en) 1994-07-12 2006-04-11 Human Genome Sciences, Inc. Connective tissue growth factor-2
PT804562E (pt) 1994-07-12 2003-02-28 Human Genome Sciences Inc Factor 2 de crescimento de tecido conjuntivo
JPH10512235A (ja) * 1994-07-20 1998-11-24 セルトリックス ファーマシューティカルズ，インコーポレイテッド 骨形成の促進および骨再造形の調節のためのｉｇｆ／ｉｇｆｂｐ複合体
US5994302A (en) * 1994-12-09 1999-11-30 Human Genome Sciences, Inc. Human vascular IBP-like growth factor
US5747280A (en) * 1995-06-05 1998-05-05 Human Genome Sciences, Inc. Human vascular IBP-like growth factor
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU762047B2 (en) 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
JP3971108B2 (ja) 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
WO2001087323A2 (fr) 2000-05-16 2001-11-22 Genentech, Inc. Procede de traitement des lesions du cartilage
CA2702192A1 (fr) 2001-03-14 2002-09-19 Genentech, Inc. Peptides antagonistes d'igf
ES2541673T3 (es) 2003-09-12 2015-07-23 Ipsen Biopharmaceuticals, Inc. Métodos para el tratamiento de la deficiencia de factor 1 de crecimiento similar a la insulina (IGF-1)
JP2007537711A (ja) 2003-10-03 2007-12-27 ジェネンテック・インコーポレーテッド Ｉｇｆ結合タンパク質
EP3681602A1 (fr) 2017-09-11 2020-07-22 Shire Human Genetic Therapies, Inc. Procédés et compositions pour traiter des maladies pulmonaires chroniques
WO2022086953A1 (fr) 2020-10-19 2022-04-28 Oak Hill Bio Limited Compositions appropriées pour une utilisation chez des nouveau-nés
IL314331A (en) 2022-01-19 2024-09-01 Oak Hill Bio Ltd Methods and compounds for reducing oxidation of IGF-1/IGFBP
WO2023242442A1 (fr) 2022-06-17 2023-12-21 Oak Hill Bio Limited Procédé de maturation/différenciation de neurones et/ou de modulation du nerf vague
WO2023242439A1 (fr) 2022-06-17 2023-12-21 Oak Hill Bio Limited Stabilisation vasculaire (nourrissons prématurés)
WO2023242440A1 (fr) 2022-06-17 2023-12-21 Oak Hill Bio Limited Traitement des poumons chez les nourrissons
WO2024170612A1 (fr) 2023-02-14 2024-08-22 Oak Hill Bio Limited Traitement de la dérégulation de cicatrisation dans un tissu gi

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3338480A1 (de) * 1983-10-22 1985-05-02 Behringwerke Ag, 3550 Marburg Neues protein pp(pfeil abwaerts)2(pfeil abwaerts)(pfeil abwaerts)0(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8908667A1 *

Also Published As

Publication number Publication date
DK131988D0 (da) 1988-03-11
AU3296589A (en) 1989-10-05
JPH03504494A (ja) 1991-10-03
DK131988A (da) 1989-09-12
WO1989008667A1 (fr) 1989-09-21

Similar Documents

Publication Publication Date Title
EP0404812A1 (fr) Proteine recombinante de liaison d'igf (facteur de croissance analogue a l'insuline) (ibp-1)
EP0246753B1 (fr) Antagonistes du facteur de croissance des fibroblastes
US5164370A (en) Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US5077276A (en) Growth factor
US6506874B1 (en) IGF-I variants
JP3366644B2 (ja) 部分的成長ホルモン不感受性症候群の治療
EP0369943A1 (fr) Protéines de liaison pour facteurs de croissance semblables à l'insuline
Smith Somatomedin carrier proteins
US20080261871A1 (en) Y2/Y4 Selective Receptor Agonists for Therapeutic Interventions
EP0546110B1 (fr) Nouvelle proteine de liaison de facteur de croissance analogue a l'insuline igfbp-5
JPH11509187A (ja) 内皮細胞増殖の調節
ZA200607492B (en) Y2/Y4 selective receptor agonists for therapeutic interventions
JPH09512008A (ja) うっ血性心不全を治療するための、成長ホルモンとインスリン様成長因子との組み合わせ
FI98731C (fi) Menetelmä superaktiivisten insuliinianalogien valmistamiseksi
US5252718A (en) Fibroblast growth factor antagonists
IE913035A1 (en) Genetic material encoding new insulin-like growth factor¹binding protein (igfbp-5)
IE913033A1 (en) Genetic material encoding new insulin-like growth factor¹binding protein (igfbp-4)
AU658187B2 (en) Human bone derived insulin like growth factor binding protein
IE913032A1 (en) New insulin-like growth factor binding protein (igfbp-4)
EP1533374A1 (fr) Nouveaux peptides avec activite de production de camp
US5693754A (en) Inhibitory binding protein for insulin-like growth factors
JP2003512291A (ja) ガレクチン１１
US6329500B1 (en) Transforming growth factor-β binding site
JPH10502623A (ja) Ｏ−グリコシル化真正ｉｇｆ−ｉおよびその切断変種、その製造方法、並びに医薬組成物
HU201566B (en) Process for producing new analoguse of activatin factor of human growth hormon and pharmaceutical and veterinair compositions containing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900911

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19920515

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920926